| Followers | 54 |
| Posts | 6684 |
| Boards Moderated | 0 |
| Alias Born | 01/11/2017 |
Thursday, May 11, 2017 6:09:25 PM
Dr. M-
At this point, it's an educated guess based on a pre-revenue company requiring at least $100MM to bring to market, including the $60M Tony mentioned to get through all the trials.
By eliminating all unknowns and speculation , the company is truly valued at $80M. That's simply the market capitalization. Regardless how strong any of us feels, and I do feel strong, the quick nickel is better than the slow dime. All the risk and financial capitalization will be on the buyer so they need enough meat on the bone to make it worthwhile. In retrospect, if CYDY was close they wouldn't sell. So it's a win/win based on market cap and what I would say is generous at 8x's value (stock price).
The science could be worth $10B per year but investors are saying "no" right now, hence a $.53 share price.
It's Neanderthal math and I admit it as I'm basing it off only a few variables but those data points are non-arguable at this point. I have close to 50k shares and got to an average price per share of $.55
Eight dollars would put a lot bread in the basket! As always, appreciate your valued input. Any time I get nervous, I read your thoughtful and well-reasoned, medically-backed posts and return to my bullish attitude!
Grip
At this point, it's an educated guess based on a pre-revenue company requiring at least $100MM to bring to market, including the $60M Tony mentioned to get through all the trials.
By eliminating all unknowns and speculation , the company is truly valued at $80M. That's simply the market capitalization. Regardless how strong any of us feels, and I do feel strong, the quick nickel is better than the slow dime. All the risk and financial capitalization will be on the buyer so they need enough meat on the bone to make it worthwhile. In retrospect, if CYDY was close they wouldn't sell. So it's a win/win based on market cap and what I would say is generous at 8x's value (stock price).
The science could be worth $10B per year but investors are saying "no" right now, hence a $.53 share price.
It's Neanderthal math and I admit it as I'm basing it off only a few variables but those data points are non-arguable at this point. I have close to 50k shares and got to an average price per share of $.55
Eight dollars would put a lot bread in the basket! As always, appreciate your valued input. Any time I get nervous, I read your thoughtful and well-reasoned, medically-backed posts and return to my bullish attitude!
Grip
Recent CYDY News
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/22/2025 10:15:23 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/17/2025 05:15:14 AM
- December 2025 Letter to Shareholders • GlobeNewswire Inc. • 12/16/2025 01:30:00 PM
